Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), clinical areas (Expand Search)
linear decrease » linear increase (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), clinical areas (Expand Search)
linear decrease » linear increase (Expand Search)
-
2161
-
2162
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2163
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2164
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2165
-
2166
-
2167
-
2168
-
2169
-
2170
-
2171
-
2172
-
2173
-
2174
-
2175
-
2176
-
2177
-
2178
-
2179
-
2180